New hope for stomach cancer: experimental drug BHB810 enters human trials
Disease control
Not yet recruiting
This study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…
Phase: PHASE1, PHASE2 • Sponsor: BigHat Biosciences, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC